Intra-Cellular Therapies (ITCI): Parkinson's Disease Drug Expansion Could Be The Next Move
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study. Read why ITCI stock is a Strong Bu...
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...
Read More
Other Stories in Business
- Farmer protest: Centre invites protesting farmers for key meeting in Chandigarh on This date - What’s on agenda?
- What Is UnoLock? The Sovereign Digital Vault Redefining Preservation
- The $TRUMP Coin: A Controversial Cryptocurrency Raises Legal and Ethical Alarms
- 10 AI Agent Tools That Are Reshaping the Industry in 2025
- Connecting Asia's startup ecosystem
- Calculating capital gains on securities traded in USD
- LTIMindtree Q3 Results Review — Motilal Oswal Reiterates 'Buy' On The Stock; Sees 29% Upside; Here's Why
- China finalises IM rules but gaps remain
- Maha Kumbh begins in Prayagraj, PM Modi extends greetings
:max_bytes(150000):strip_icc()/BTCUSDChart-9424c0db59134e7eae609ec65bc1a7e8.gif)
